May 6: The Week in Cancer News
Adolescents and young adult cancer survivors at higher risk for dying from a new cancer diagnosis, and FDA grants full approval to Enhertu for metastatic HER2-postive breast cancer.
Progress Against Cancer
Adolescents and young adult cancer survivors at higher risk for dying from a new cancer diagnosis, and FDA grants full approval to Enhertu for metastatic HER2-postive breast cancer.
The FDA has granted full approval to an antibody-drug conjugate for certain patients with breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of certain adult...
As outcomes improved for cancer patients in states that expanded Medicaid, disparities in survival disappeared.
FDA proposes ban on menthol cigarettes, and other stories from the week in cancer news.
Study finds a connection between bacteria and fast-growing prostate cancer, and researchers measure underrepresentation of Black patients in clinical trials.
A symposium at the AACR Annual Meeting explores how social factors contribute to elevated risk of cancer in some populations.
Researchers are investigating how to match specific dietary changes with therapy to impede cancer progression.
Legislation to speed cancer drug development for children and adolescents requires drug companies to test drugs in children, but trials in people under 18 may take years to generate results.
DNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
An AACR Annual Meeting 2022 session highlights the impact of research advocacy partnerships for a variety of cancers.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More